Abstract
Preliminary data from a phase I trial of MEDI5752, a bispecific antibody targeting both PD-1 and CTLA4, indicate the drug is well tolerated and active, with durable responses seen across diverse tumor types.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.
